INTRODUCTION: Angiogenesis (AG) is essential for epithelial ovarian cancer (EOC) development. Vascular endothelial growth factor (VEGF), encoded by the VEGF gene, and endostatin, the product of the COL18A1 gene, act as a potent promoter and an inhibitor of AG, respectively. In the present study, we tested whether VEGF C936T and COL18A1 D104N polymorphisms alter the risk of EOC. METHODS: Genomic DNA from 131 EOC patients and 137 controls were analyzed by polymerase chain reaction and restriction fragment length polymorphism methods. The differences between groups were analyzed by χ (2) or Fisher's exact test and logistic regression analysis. RESULTS: The frequency of the VEGF 936CC genotype was higher in patients than in controls (84.8% vs. 75.3%, P = 0.03). Individuals with respective genotypes had a 1.98 (95% CI 1.04-3.78)-fold increased risk of EOC than those with the remaining genotypes. An excess of VEGF 936CC plus COL18A1 DN genotype was seen in patients when compared to controls (48.6% vs. 30.5%); however, only a tendency toward a statistically significant difference in genotype frequencies was found in the study (P = 0.06), reflecting a trend toward an increased risk of 2.44 for EOC in carriers of the combined genotype. CONCLUSION: Our data present, for the first time, preliminary evidence that VEGF C936T alone or combined with the COL18A1 D104N polymorphism of AG constitutes an important inherited EOC determinant.
INTRODUCTION: Angiogenesis (AG) is essential for epithelial ovarian cancer (EOC) development. Vascular endothelial growth factor (VEGF), encoded by the VEGF gene, and endostatin, the product of the COL18A1 gene, act as a potent promoter and an inhibitor of AG, respectively. In the present study, we tested whether VEGFC936T and COL18A1D104N polymorphisms alter the risk of EOC. METHODS: Genomic DNA from 131 EOC patients and 137 controls were analyzed by polymerase chain reaction and restriction fragment length polymorphism methods. The differences between groups were analyzed by χ (2) or Fisher's exact test and logistic regression analysis. RESULTS: The frequency of the VEGF 936CC genotype was higher in patients than in controls (84.8% vs. 75.3%, P = 0.03). Individuals with respective genotypes had a 1.98 (95% CI 1.04-3.78)-fold increased risk of EOC than those with the remaining genotypes. An excess of VEGF 936CC plus COL18A1 DN genotype was seen in patients when compared to controls (48.6% vs. 30.5%); however, only a tendency toward a statistically significant difference in genotype frequencies was found in the study (P = 0.06), reflecting a trend toward an increased risk of 2.44 for EOC in carriers of the combined genotype. CONCLUSION: Our data present, for the first time, preliminary evidence that VEGFC936T alone or combined with the COL18A1D104N polymorphism of AG constitutes an important inherited EOC determinant.
Authors: J Dixelius; H Larsson; T Sasaki; K Holmqvist; L Lu; A Engström; R Timpl; M Welsh; L Claesson-Welsh Journal: Blood Date: 2000-06-01 Impact factor: 22.113
Authors: Gustavo J Lourenço; Cassio Cardoso-Filho; Neiva S L Gonçales; Julia Y Shinzato; Luis C Zeferino; Helvia Nascimento; Fernando F Costa; Maria S C Gurgel; Carmen S P Lima Journal: Breast Cancer Res Treat Date: 2006-06-29 Impact factor: 4.872
Authors: Maria Eduarda Lopes Baitello; Graciele Domitila Tenani; Rafael Fernandes Ferreira; Victor Nogueira; Marcela Augusta de Souza Pinhel; Rita de Cássia Martins Alves da Silva; Renato Ferreira da Silva; Patrícia da Silva Fucuta; Moacir Fernandes de Godoy; Dorotéia Rossi Silva Souza Journal: Can J Gastroenterol Hepatol Date: 2016-08-31